Lifecare AS (DE:LFC) has released an update.
Lifecare ASA, a medical sensor company, has successfully enhanced the read-out distance for their next-gen Continuous Glucose Monitor, paving the way for a pivotal longevity study on dogs. The study, set to begin in mid-June at the Norwegian University of Life Sciences, marks a significant step towards the veterinary market product readiness. The accomplishment comes after dedicated efforts from the Lifecare team and specialized consultants to meet product development requirements.
For further insights into DE:LFC stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
